TO TRADENT

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

spond to a collection of information Con	nplete if Known	
Application Number	10/018,034	
Filing Date	07/23/2002	
First Named Inventor	R. Kobylecki	
Art Unit	2857	
Examiner Name	D. Elias	
Attorney Docket Number	1795	

Sheet	1		of_		12	/ (tionio)	
Sileet					II S DATENT	DOCUMENTS	Octomes Lines Where
Examiner	Cite No.	Docume	ent Nu	mber	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
nitials*	NO.	Number-Kir	nd Code	9 ² (f known)			
ED	_	US- 2001/00	1663	11	08/23/2001	Freitag et.	
<u> </u>		US- 2001/00	5577	' 5	12/27/2001	Schultz et al.	
<u> </u>		US- 2002/00			03/14/2002	Mansky et al.	
	_	US- 2002/00			03/28/2002	Hwang et al.	
<u> 52</u>	-	US- 2003/00			02/13/2003	Agrafiotis et al.	
20	-	US- 2003/02			11/27/2003	Giaquinta et al.	
<u>88</u>	 -	US- 3,899,0			08/12/1975	Curtiss	
<u> </u>	_	US- 4,399,6			08/23/1983	Collins	ļ
<u>Q3</u>	-	US- 4,835,7			05/30/1989	Hutchins et al.	
<u>&3</u>	 -	US- 4,835,7			10/31/1989	Hayes et al.	
ED	-	1			05/23/1995	Bojanic et al.	
83	<u> </u> =	US- 5,417,9			08/29/1995	Fodor et al.	<u> </u>
B3		US- 5,445,9			10/31/1995	Agrafiotis et al.	
CD.	<u> </u>	US- 5,463,			11/12/1996	Agrafiotis et al.	
83		US- 5,574,			08/19/1997	Hayes et al.	
50		US- 5,658,			11/04/1997	Agrafiotis et al.	
દુશ		US- 5,684,				Fodor et al.	
82	_	^{US-} 5,744,			04/28/1998	Sickinger et al.	
20	Τ_	US- 5,763,	278		06/09/1998		
22		US- 5,807	522		09/15/1998	Brown et al.	

Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	MENTS Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	7
00	-	Country Code ³ Number ⁴ Kind Code ⁵ (if known) EP 0807811 A2	11/19/1997	Pfizer		┢
<u>88</u>	+	EP 0921396 A2	06/09/1999	Pfizer		╫
<u> </u>	-	WO 00/03240	01/20/2000	Cetek		╆
<u>ED</u>	╀	WO 94/11489	05/26/1994			╈
<u> 22</u>	+-	WO 96/06842		Harding et al.	-	╆
<u>ED</u> .	+=	WO 96/16078	05/30/1996	Kobylecki et al	<u> </u>	

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of Considered. Include copy of this form with next communication to applicant. Applicant sunded the two-letter code (WIPO Standard ST.3). For USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precode the serial number of the patent document. Applicant is to place a check mark here if English language the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language to the symbols as indicated on the document under WIPO Standard ST.16 if possible.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments including gathering, preparing, and submitting the complete displaying for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent on the Information

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Sheet

PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE perwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known				
Application Number	10/018,034			
Filing Date	07/23/2002			
First Named Inventor	R. Kobylecki			
Art Unit	2857			
Examiner Name	D. Elias			
Attorney Docket Number	1795			

			U. S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
80	_	^{US-} 5,832,182	11/03/1998	Zhang et al.	
8,8	-	^{US-} 5,843,767	12/01/1998	Beattie	
ED)	-	^{US-} 5,859,703	01/12/1999	Aldridge et al.	
<i>ED</i>	_	^{US-} 5,901,069	05/04/1999	Agrafiotis et al.	
<i>ED</i>	_	^{US-} 5,928,952	07/27/1999	Hutchins et al.	
යි.	_	^{US-} 5,956,137	09/21/1999	Lim et al.	
ED	_	^{US-} 5,965,137	10/12/1999	Petrus	
E,D	_	^{US-} 5,985,214	11/16/1999	Stylli et al.	
20	_	^{US-} 5,999,255	12/07/1999	Dupee et al.	
9,8	_	^{US-} 6,003,029	12/14/1999	Agrawal et al.	
ಟ	_	^{US-} 6,100,901	08/08/2000	Mohda et al.	
20	_	^{US-} 6,140,643	10/31/2000	Brown et al.	
2D ED	_	^{US-} 6,175,816	01/16/2001	Flavin et al.	
ED	_	^{US-} 6,267,935	07/31/2001	Hol et al.	
68	_	^{US-} 6,296,673	10/02/2001	Santarsiero et al.	
20	_	US- 6,327,334	12/04/2001	Murray, Jr. et al.	-
وي		^{US-} 6,333,501	12/25/2001	Labrenz	
EN	_	^{US-} 6,421,553	07/16/2002	Costa et al.	-
82	-	^{US-} 6,434,490	08/13/2002	Agrafiotis et al.	

		FORE	IGN PATENT DOCL	MENTS		
Examiner Cite Initials* No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	١.	
		Country Code ³ Number ⁴ Kind Code ⁵ (# known)	MM-DD-YYYY		Or Relevant Figures Appear	7
24		WO 98/40159	09/17/1998	Lebl et al.		Ŀ
20		WO 98/47613	10/29/1998	Wu et al.	-	Ŀ
8,8		WO 98/52614	11/26/1998	Rothbard et al.		Ŀ
رکړي		WO 99/04247	01/28/1999	Neilsen		Ľ
820		WO 99/06814	02/11/1999	Loewy et al.		Ŀ
60		WO 99/08112	02/18/1999	Alakov et al.	_	

Date Examiner 03 Considered Signature

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 'Applicant is to place a check mark here if English language Translation is attached. Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

& TRADEAN

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

work Reduction Act of 1995, no persons are required to re	second to a collection of informati	nark Office; U.S. DEPARTMENT OF COMMENCE ion unless it contains a valid OMB control number. Inplete if Known
orm 1449/PTO	Application Number	10/018,034
	Filing Date	07/23/2002
MATION DISCLOSURE	First Named Inventor	R. Kobylecki
MENT BY APPLICANT	Art Unit	2857
Ise as many sheets as necessary)	Examiner Name	D. Elias
ise as many energy	Attorney Docket Number	1795

	3		of	1	2	Allomey Docker Humber	
Sheet	<u> </u>					- COUNTY COUNTY	
					U. S. PATENT	DOCUMENTS Name of Patentee or	Pages, Columns, Lines, Where
Examiner Initials*	Cite No.1	Docume			Publication Date MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
,,,,,,		Number-Kin	d Code	2 (# icnown)		1	
80		^{US-} 6,487,52	23		11/26/2002	Jarman et al.	
		US- 2002/00-		A1	04/25/2002	Cima et al.	+=
<u>60</u>		US- 6,507,63			01/14/2003	Lehmann	
2,0		US-					
		US-					
		US-					
		US-					
	<u> </u>	US-					
	\vdash	US-					
	+	US-					
	┼	US-					
	┼	US-			_		
	↓						
		US-					
		US-					
	1	US-					
	\top	US-					
	+-	US-					
	+-	US-					_
		US-					

Examiner Initials*	Cite No.	Foreign Patent Document	PATENT DOCU Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	™
الكرع		Country Code ³ Number ⁴ Kind Code ⁵ (if known) WO 99/45379	100,101,000	Nienaber et al.		F
2,0		WO 99/45389	00.10	Nienaber et al.		+-
ED		WO 98/18549	00/01/1000	Okamota Glaxo Group		E
8,0	Ξ	WO 00/67872	11/16/2000	Glaxo Gloup		L
	<u> </u>		 			1

		Date	10101/2005
Elass	$\Omega \Omega = \Omega + \Omega$	Considered	03/24/2005
Examiner	Wine Nosla		the state of the s
Signature	CCCCCC CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC	w line through	citation if not in conformance and no

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of Considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of Considered. Include copy of this form with next communication to applicant to the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by Japanese patent documents, the indication of the year of the reign of the year of th

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, uspect of the USPTO. Time will vary depending upon the individual case. Any comments including gathering, preparing, and submitting the complete dapplication form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent on the USPTO. This collection is estimated to take 2 hours to complete the sent of the USPTO. This collection is estimated to take 2 hours to complete the sent of the USPTO. This collection is estimated to take 2 hours to complete this collection is estimated to take 2 hours to complete this collection is estimated to take 2 hou

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** 10/018,034 INFORMATION DISCLOSURE **Filing Date** 07/23/2002 STATEMENT BY APPLICANT First Named Inventor R. Kobylecki Art Unit 2857 (Use as many sheets as necessary) **Examiner Name** Elias Desta Attorney Docket Number Sheet 1795 12 4

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
88	-	PETTY, C.J. et al., "Applications of FT-Raman Spectroscopy in the Pharmaceutical Industry."	
وي	-	MARTIN, P.A. et al., "Automation of Microtiter Plate-Chromogenic Substrate LAL Endotoxin Assay Method by Use of a Modified Cetus Pro/Pette Express System",	_
82	-	Journal of Parenteral Science & Technology, Vol. 40, No. 2, March-April 1986, pp. 61-66.	-
6,3	-	LENCZEWSKI, M. et al. "Automated Screening Method for Determining Optimum Preservative Systems for Personal and Home Care Products",	
اله ع	_	Journal of AOAC International, Vol. 81, No. 3, 1998, pp. 534-539.	_
ه٤	_	LENNERNAS, H., "Human Intestinal Permeability", Journal of Pharmaceutical Sciences, Vol. 87, No. 4, 1998, pp. 403-410	
2,8	_	GEORGE, R. et al. "Automated dissolution testing of sustained release tablets", American Laboratory, Circular Reader Service, Card No. 17, February 1988, pp. 106-112	
٤۵	_	YARMAMURA, R. et al. "Receptor Binding as a Primary Drug Screen", Neurotransmitter Receptor Binding, 2d ed. Raven Press, 1985, pp. 189-233	
23	_	"Department of Health and Human Services", Federal Register, Vol. 62, No. 85, 1997, pp. 24302-24309	
&3	_	ECKSTEIN, R. J. et al. "Unattended, Robotic Drug-Release Testing of Enterically Coated Aspirin", Analytical Chemistry, Vol. 58, No. 11, September 1986, pp. 2316-2320	

Examiner		Date	03/2//2000
	Elias Desle	Considered	03/24/2005
Signature	Cities adelle	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy or this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE are Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	e for form 1449/P1			Complete if Known		
30030101	0 101 1011111 144301	.0		Application Number	10/018,034	
INFO	ORMATIC	ON DIS	CLOSURE	Filing Date	07/23/2002	
STA	TEMENT	BY A	PPLICANT	First Named Inventor	R. Kobylecki	
				Art Unit	2857	
(Use as many sheets as necessary)				Examiner Name	D. Elias	
Sheet	5	of	12	Attorney Docket Number	1795	

-		NON DATENT LITED ATUDE DOCUMENTS				
Examiner Initials*	Cite No.1	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			
83	-	SONG, C.X. et al. "Controlled release of U-86983 from double-layer biodegradable matrices: effect of additives on release mechanism and kinetics",				
83	_	Journal of Controlled Release, Vol. 45, (1997), pp. 177-192				
8,3	_	GOLD, G. et al., "Effects of Selected U.S.P. Talcs on Acetylsalicylic Acid Stability in Tablets", Journal of Pharmaceutical Sciences, Vol. 53, No. 1, January 1964, pp. 52-54				
82	_	WARD, K. et al., "Automatic Preparation of Protein Crystals Using Laboratory Robotics and Automated Visual Inspection", Journal of Crystal Growth, Vol. 90 (1988), pp 325-339				
E.D	-	OTSUKA, M. et al., "Physicochemical Characterization of Glybuzole Polymorphs and Their Pharmaceutical Properties", Research Paper, Marcel Dekker, Inc. 1999, pp. 197-203				
823	_	LITTLECHILD, J.A., "Protein Crystallization: Magical or Logical: Can We Establish Some General Rules?",				
ED	-	Journal of Physics D: Applied Physics, Vol. 24, No. 2, February 1991, pp. 111-118	^			
8.8	_	CHAYEN, Naomie E. et al., "Microbatch Crystallization Under Oil - A New Technique Allowing Many Small-Volume Crystallization Trials",	_			
42	-	Journal of Crystal Growth, Vol. 122, Nos. 1-4, August 1992 pp. 176-180				
۵٤	-	CRAW, S. et al., "Cased-Based Design for Tablet Formulation", pp. 358-369.	_			

Examiner Signature	Elices Desta	Date Considered	03/24/2005

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional).

2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO

Substitute for form 1449/PTO

Application Number 10/018,034

INFORMATION DISCLOSURE Filing Date 07/23/2002

STATEMENT BY APPLICANT First Named Inventor R. Kobylecki

Art Unit 2857

Art Unit 2857

Examiner Name D. Elias

Sheet 6 of 12 Attorney Docket Number 1795

		NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
. 80	-	YAKOVLEV, Y. et al., "A Laboratory Apparatus for Crystal Growth from Solution", Instruments and Experimaental Techniques, Vol. 41, No. 2, 1998, pp. 292-296			
60	_	FINDLAY, W. et al., "Utilization of Fourier transform-Raman spectroscopy for the study of pharmaceutical crystal forms"	1		
هع	_	Journal of Pharmaceutical and Biomedical Analysis, Vol. 16 (1998) pp. 921-930	_		
920	_	FERWERDA, R., et al. "The Use of FT-Raman Spectroscopy and Chemometric Procedures in the Analysis of Pharmaceuticals, Nicolet FT-Raman, (1997))		
rD	_	TISONE, T, "Dispensing Systems for Miniaturized Diagnostics", IVD Technology Magazine, May 1998			
8.8		SORIANO, T. et al., "ASTEC: an Automated System for Sitting-Drop Protein Crystallization", Journal of Applied Crystallography, Vol, 26, 1993, pp. 558-562	_		
83	_	STEWART, P. et al., "Practical Experimental Design Techniques for Automatic and Manual Protein Crystallization", Journal of Crystal Growth, Vol. 196, 1999, pp. 665-673			
4.8	_	RUBIN, B. et al., "Minimal Intervention Robotic Protein Crystallization", Journal of Crystal Growth, Vol. 110, 1991, pp. 156-163	(
EQ	-	PETTY, C. et al., "The use of FT-Raman Spectroscopy in the Study of Formulated Pharmaceuticals", Nicolet Instruments of Discovery, Nicolet Instrument Corporation (1991)			
20	_	CARRIE et al., "An Automated Sampling Device for Dissolution Testing" J. of Pharmaceutical Sciences, Vol. 72, No. 8, August 1983, pp. 976-988.	_		

Examiner Elice Desta	Date Considered	03/24/2005
----------------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

_	te for form 1449/PTO			e required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known		
Substitut	18 101 101111 1443/1 10			Application Number	10/018,034	
INFO	ORMATION	DIS	CLOSURE	Filing Date	07/23/2002	
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	R. Kobylecki	
	##			Art Unit	2857	
	(Use as many she	ets as n	lecessary)	Examiner Name	D. Elias	
Sheet	7	of	12	Attorney Docket Number	1795	

		NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
ED	_	OLDFIELD, T.J. et al., "A Flexible Approach to Automated Protein Crystallization", Journal of Applied Crystallization, Vol. 24, 1991, pp. 255-260	_		
QQ	_	MORRIS, D.W. et al., "Automation of Protein Crystallization Trials: Use of a Robot to Deliver Reagents to a Novel Multi-Chamber Vapor Diffusion Plate",			
620	_	Product Application Focus, BioTechniques, Vol. 7, No. 5, (1989), pp. 522-527	_		
ad	_	NEWMAN, A., "Send in the Robots", Analytical Chemistry, Vol. 62, No. 1, January 1, 1990, pp. 29A - 34A.			
ED	_	McPHERSON, A., "Two Approaches to the Rapid Screening of Crystallization Conditions", Journal of Crystal Growth, Vol. 122, (1992) pp. 161-167			
82	_	LINDSEY, J.S. et al., "Robotic work station for microscale synthtic chemistry: On-line absorption spectroscopy, quantitative automated thin-layer chromatography,			
4.8	_	and multiple reactions in parallel", Rev. Sci. Instrum., Vol. 59, No. 6, June 1988, pp. 940-950			
8.8	_	KELDERS, H. et al., "Automated protein crystallization and a new crystal form of a subtilisin:eglin complex", Protein Engineering, Vol. 1, No. 4, 1987, pp. 301-303	_		
8.8	-	JANCARIK, J. et al., "Sparse matrix sampling: a screening method for crystallization fo proteins", Journal of Applied Crystallization, Vol. 24, 1991, pp. 409-411.	(
620	-	BOWTELL, David D.L., "Options available-from start to finish-for Obtaining Expression Data by Microarray", Peter MacCallum Cancer Institute, pp. 25-32			

Examiner	00: 0	Date	13/24/2025
Signature	Elias Desla	Considered	00/04/000

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

O Entire	te for form 1449/PT	0			Complete if Known
	10 10 10 10 11 17 17 1			Application Number	10/018,034
INFO	ORMATIO	N DIS	CLOSURE	Filing Date	07/23/2002
STA	TEMENT	BY A	PPLICANT	First Named Inventor	R. Kobylecki
				Art Unit	2857
	(Use as many	sneets as n	ecessary)	Examiner Name	D. Elias
Sheet	8	of	12	Attorney Docket Number	1795

		NON DATERIO LITERATURE DOCUMENTO			
Examiner Initials*	Cite No. ¹	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
G3)	GONZALEZ, F. et al., "Crocodile: An Automated Apparatus for Organic Crystal Growth from Solution", Acta Astronautica, Vol. 25, No. 12, 1991, pp. 775-784			
(مع	_	GILLILAND, G. et al., "Biological Macromolecule Crystallization Database, Version 3.0: New Features, Data and the NASA Archive for Protein Crystal Growth Data",			
وړی	_	Acta Crystallization Section D, 1994, pp. 408-413			
کی		ZHU, H. et al., "Influence of water activity in organic solvent water mixtures on the nature of the crystallizing drug phase 1. Theophylline",	<u> </u>		
હુુ		International Journal of Pharmaceutics, Vol. 135, January 1996, pp. 151-160			
83	-	CUDNEY, B. et al., "Screening and Optimization Strategies for Macromolecular Crystal Growth",			
8,3	-	Acta Crystallographica Section D, Vol. D50, 1994, pp. 414-423			
E&	_	COX, M.J. et al., "Experiments with Automated Protein Crystallization", Journal of Applied Crystallography, Vol. 20, 1987, pp. 366-373	_		
83	_	CHAYEN, N. et al., "New Developments of the IMPAX Small-Volume Automated Crystallization System", Acta Crystallographica Section D, Vol. D50, 1994, pp. 456-458			
که2	_	CHAYEN, N. et al., "An Automated System for Micro-Batch Protein Crystallization and Screening", Journal of Applied Crystallography, Vol. 23, 1990, pp. 297-302			

Examiner	$\Omega \Lambda \cdot \Lambda \sigma$	Date	03/24/2005
Signature	Elias Desla	Considered	0-70-17000

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

S STEMPS	e for form 1449/PT	· O			Complete if Known		
MARINE	10 101 10111 14431 1	J		Application Number	10/018,034		
INFO	DRMATIC	N DIS	CLOSURE	Filing Date	07/23/2002		
STA	TEMENT	BY A	PPLICANT	First Named Inventor	R. Kobylecki		
	// the se	-64		Art Unit	2857		
(Use as many sheets as necessary)				Examiner Name	D. Elias		
Sheet	9	of	12	Attorney Docket Number	1795		

JAN 1 1 2005

		NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
ED	·—	CASAY, G.A. et al., "Laser Scattering in a Hanging Drop Vapor Diffusion Apparatus for Protein Crystal Growth in a Microgravity Environment",			
6,3	—	Journal of Crystal Growth, Vol. 122, 1992, pp. 95-101			
88	1	BULLOCK, E. et al., "Apparatus for the growth of crystals from small volumes of solution", Journal of Physics E, Scientific Instruments, Vol. 5, 1972, pp. 412-413			
ED	-	BRODERSEN, D.E. et al., "XAct: a program for construction, automated setup and bookkeeping of crystallization experiments",			
کرع	_	Journal of Applied Crystallography, Vol. 32, 1999, pp. 1012-1016			
ED	_	BECKMANN, W. et al., "The Effect of Additives on Nucleation: A Low Cost Automated Apparatus", Journal of Crystal Growth, Vol. 99, 1990, pp. 1061-1064			
83	_	LONGMIRE, M.L. et al., "Polymorph Analysis by Dispersive Raman Spectroscopy", Nicolet Instruments of Discovery			
کی	_	ANDERSEN G.R. et al., "A Spreadsheet Approach to Automated Protein Crystallization", Journal of Applied Crystallography, Vol. 29, 1996, pp. 236-240			
82	_	ALDRIDGE, P.K. et al., "A Robotic Dissolution System with On-Line Fiber-Optic UV Analysis", J. of Pharmaceutical Sciences, Vol. 84, No. 8, August 1995			
ED	_	BOWTELL, D., "Options Available from Start to Finish for Obtaining Expression Data by Microarray", Nature Genetics Supplement, Vol. 21, January 1999, pp. 25-32	_		

	Examiner Signature		Date Considered	03/24/2005
--	-----------------------	--	--------------------	------------

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

aperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** 10/018,034 Filing Date INFORMATION DISCLOSURE 07/23/2002 STATEMENT BY APPLICANT **First Named Inventor** R. Kobylecki **Art Unit** 2857 (Use as many sheets as necessary) **Examiner Name** D. Elias Attorney Docket Number Sheet 12 1795 10 of

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
20	1	MORRIS, K. et al., "An Integrated Approach to the Selection of Optimal Salt Form for a New Drug Candidate", International Journal of Pharmaceutics, Vol. 105, 1994, pp. 209-217	
200	_	LAMPARTER, E. et al., "The Automation of Dissolution Testing of Solid Oral Dosage Forms", J. of Pharamceutical & Biomedical Analysis, Vol. 10, Nos. 10-12, 1992, pp. 727-73	,
وچی	~	DE CASTRO, M.D. et al., "Automation fo pharmaceutical dissolution testing by flow injection analysis",	
82	_	Journal of Pharmaceutical & Biomedical Analysis, Vol. 8, No. 4, 1998, pp. 329-336	
ولي	-	LO, Su-Chin, et al., "Automated Drug Dissolution Monitor That Uses a UV-Visible Diode Array Spectrophotometer",	
22	•	Journal of Pharmaceutical Sciences, Vol. 82, No. 4, April 1993, pp. 350-354.	
هع	-	PAPAS, A.N. et al., "Evaluation of Robot Automated Drug Dissolution Measurements", American Chemical Society 1995, pp. 14081411	_
ED	_	SHAH, K.P. et al., "Automated analytical systems for drug development studies 3. Multivessel dissolution testing system based on microdialysis sampling",	_
೭ವಿ	-	Journal of Pharmaceutical and Biomedical Analysis, Vol. 13, 1995, pp. 1235-1241	_
ED	-	MANN, M., "Quantitative proteomics?" Nature Biotechnology, Vol. 17, October 1999, pp. 954-955	_

Examiner	$\Omega \Lambda = \Omega \Lambda$	Date	13/24/2005
Signature	Elias Desler	Considered	03/04/0000

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PARE THE FOR FORM 1449/PTO				Complete if Known		
10003	8 101 101111 144317 10			Application Number	10/018,034	
INFO	DRMATION	DIS	CLOSURE	Filing Date	07/23/2002	
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	R. Kobylecki	
				Art Unit	2857	
(Use as many sheets as necessary)			ecessary)	Examiner Name	D. Elias	
Sheet	11	of	12	Attorney Docket Number	1795	

		NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
20	_	SHAH, K.P. et al., "Automated analytical systems for drug development studies II- A system for dissolution testing",			
88	_	Journal of Pharmaceutical & Biomedical Analysis, Vol. 12, No. 12, 1994, pp. 1319-1527	_		
603	_	FODOR, S. et al., "Light-Directed Spatially Addressable Parallel Chemical Synthesis", Research Article,	_		
SD OLS	-	American Association for the Advancement of Science, Vol. 251, No. 4995, February 1991, pp. 767-773			
کی		FODOR, S., "Massively Parallel Genomics", American Association for the Advancement of Science, Vol. 277, No. 5324, July 1997, pp. 393-395			
٤D	_	MARSHALL, A. et al., "DNA chips: An array of possibilities", Nature Biotechnology, Vol. 18, January 1998, pp. 27-31			
ED	_	RAMSAY, G., "DNA chips: State-of-the art", Nature Biotechnology, Vol. 16, January 1997, pp. 40-44			
90	-	PERSIDIS, A., "An ambitious drug development platform attempts to link gene sequence to expressed phenotype under various physiological states",			
40	-	Nature Biotechnology, Vol. 16, April 1998, pp. 393-394	_		
EB	-	CHEUNG, V.G. et al., "Making and reading microarrays", Nature Genetics Supplement, Vol. 21, January 1999, pp. 15-19	_		

Examiner Signature	Eliae Desta	Date Considered	03/24/2005

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. Do NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known for form 1449/PTO **Application Number** 10/018,034

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

12

Sheet

12

iling Date	07/23/2002		
irst Named Inventor	R. Kobylecki		
Art Unit	2857		
xaminer Name	D. Elias		
Attorney Docket Number	1795		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
20		FRANK, R., "Simultaneous and Combinatorial Chemical Synthesis Fechniques for the Generation and Screening of Molecular Diversity",	
820	_	Journal of Biotechnology, Vol. 41, 1995, pp. 259-272	
2,80		COX, M.J. et al., "An Investigation of Protein Crystallization Parameters Using Successive Automated Grid Searches (SAGS)",	_
60	_	Journal of Crystal Growth, Vol. 90, Nos. 1-3, (1988), pp. 318-324.	
920		ZEELEN, J. et al., "Crystallization Experiments with 2-Enoyl-CoA Hydratase, Using an Automated Fast-Screening Crystallization Protocol",	
90	_	Acta Crystallographica, Section D, 1994, pp. 443-447.	_
220	_	BRIGGS, J. et al., "The Temperature-Composition Phase Diagram and Mesophase Structure Characterization of the Monoolein/Water System",	_
98		J. Phys. II France, Vol. 6, May 1996, pp. 723-751	
58			
50	_		-

Examiner	00: 0	Date	03/24/0mc
Signature	Chas Wesler	Considered	00/01/2000

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered, include copy or this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.